Relapse, Non-Relapse and Treatment Outcomes in a Real-World Neuromyelitis Optica Spectrum Disorder Cohort (P7-8.001)
Characterize relapse and non-relapse hospitalizations and evaluate the efficacy and safety of rituximab, eculizumab, inebilizumab, satralizumab, mycophenolate mofetil (MMF), and azathioprine.
Authors
- Danielle Kei Pua
- Philippe‐Antoine Bilodeau (ORCID: https://orcid.org/0000-0002-2672-554X)
- Sathya Narasimhan
- Farrah Jasmine Mateen (ORCID: https://orcid.org/0000-0002-4293-8115)
- Shamik Bhattacharyya (ORCID: https://orcid.org/0000-0001-8047-3622)
- Michaël Levy (ORCID: https://orcid.org/0000-0003-2766-5777)
- Mattia Wruble
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Baylor College of Medicine (US)
- Massachusetts General Hospital (US)
- Mass General Brigham (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211203
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00